TAO Synergies (TAOX) Intangibles (2025 - 2026)
TAO Synergies' (TAOX) quarterly Intangibles came in at $16.8 million in Q2 2026, up 274.74% on a YoY basis from $4.5 million in Q2 2025, and down 33.18% quarter-over-quarter from $25.2 million in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Intangibles (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Intangibles for 2 consecutive years, with $16.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Intangibles rose 274.74% year-over-year to $16.8 million; the trailing twelve-month figure through Jun 2026 stood at $16.8 million (up 274.74% YoY), and the FY2025 full-year result was $17.9 million, changed N/A from the prior year.
- Intangibles eased to $16.8 million in Q2 2026 per TAOX's latest filing, from $25.2 million in the prior quarter.
- Across five years, Intangibles topped out at $25.2 million in Q1 2026 and bottomed at $4.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.59 Bn | 197.60 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 181.18 Bn | 178.00 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.46 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 61.66 Bn | 56.47 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.95 Bn | 30.64 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.27 Bn | 29.98 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.82 Bn | 29.82 Bn | 1.16 Mn | - |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 16.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.81 Mn |
| Mar 31, 2026 | 25.16 Mn |
| Dec 31, 2025 | 17.93 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Jun 30, 2025 | 4.49 Mn |